$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
阿昔替尼(英立达)治疗晚期肾癌患者的疗效
2025-10-19 11:44:20
Check Details
索坦(舒尼替尼)治疗肾癌的优势
2025-10-19 11:44:20
Check Details
阿昔替尼一线治疗肾细胞癌患者
2025-10-19 11:44:20
Check Details
不同癌症患者服用舒尼替尼的剂量也是不同
2025-10-19 11:44:20
Check Details
舒尼替尼获批治疗肾癌的优势
2025-10-19 11:44:20
Check Details
索拉非尼晚期肾癌的一线药物
2025-10-19 11:44:20
Check Details
肾癌患者治疗靶向药物阿昔替尼的治疗效果
2025-10-19 11:44:20
Check Details
索拉非尼治疗肾癌的效果明显优于安慰剂
2025-10-19 11:44:20
Check Details
肾癌新型靶向药物阿昔替尼
2025-10-19 11:44:20
Check Details
高血压的肾癌晚期患者需要注意什么?
2025-10-19 11:44:20
Check Details
肾癌患者饮食注意事项
2025-10-19 11:44:20
Check Details
帕唑帕尼与索坦(舒尼替尼)治疗肾癌的临床数据
2025-10-19 11:44:20
Check Details
1
2
...
2112
2113
2114
2115
2116
2117
2118
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
2
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
3
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
7
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
8
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
9
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
10
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
11
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
12
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity